Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Клиническое значение лекарственной формы индапамида модифицированного высвобождения – Арифон ретард
Клиническое значение лекарственной формы индапамида модифицированного высвобождения – Арифон ретард
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Полный текст
Список литературы
1. Bataillard A, Schiavi P, Sassard J. Pharmacological properties of indapamide. Clin Pharmacokinet 1999; 37 (suppl. 1): 7–12.
2. Damien G, Huet de Barochez B, Schiavi P. Galenic development and pharmacokinetic profile of indapamide sustained release 1,5 mg. Clin Pharmacokinet 1999; 37 (suppl. 1): 13–9.
3. Donnelly R. Clinical implications of indapamide sustained release 1,5 mg in hypertension. Clin Pharmacokinet 1999; 37 (suppl. 1): 21–32.
4. Jaillon P, Asmar R et al. Доклад на Европейском Обществе по артериальной гипертензии, Милан, 2001.
5. Emeriau J-P, Knauf H, Pujadas JO et al. A comparison of indapamide SR 1,5 mg with both amlodipine 5 mg and hydrochlorothiazide 25 mg in elderly hypertensive patients: a randomized double-blind controlled study. J Hypertens 2001; 19: 343–50.
6. Gosse P, Sheridan DJ, Zannad F et al. Regression of left ventricular hypertrophy in hypertensive patients treated with indapamide SR 1,5 mg versus enalapril 20 mg: the LIVE study. J Hypertens 2000; 18: 1465–75.
7. Marre M, Puig JG, Kokot F et al. Equivalence of indapamide SR and enalapril on microalbuminuria reduction in hypertensive patients with type2 diabetes: the NESTOR study. J Hypertens 2004; 22: 1613–22.
8. Beckett N, on behalf of HYVET Co-ordinating center, committees and investigators. Progress report of the hypertension in very elderly trial (HYVET). J Hypertens 2007; 25 (suppl. 2): S 233.
9. Ambrosioni E, Safar M, Degaute J-P et al. Low-dose antihypertensive therapy with 1,5 mg sustained-release indapamide: results of randomized double-blind controlled studies. European Study Group. J Hypertens 1998; 16: 1677–84.
10. Weidmann P. Metabolic profile of indapamide sustained-release in patients with hypertension. Drug Safety 2001; 24: 1155–65.
11. Leonetti G. Clinical positionning of indapamide sustained release 1,5 mg in management protocols for hypertension. Drugs 2000; 59 (suppl. 2): 27–38.
12. Петров В.И., Недогода С.В., Сабанов А.В. Ретроспективный клинико-экономический анализ результатов клинических исследований гипотензивных препаратов. Клин. исследования. 2004; 3–4: 36–43.
2. Damien G, Huet de Barochez B, Schiavi P. Galenic development and pharmacokinetic profile of indapamide sustained release 1,5 mg. Clin Pharmacokinet 1999; 37 (suppl. 1): 13–9.
3. Donnelly R. Clinical implications of indapamide sustained release 1,5 mg in hypertension. Clin Pharmacokinet 1999; 37 (suppl. 1): 21–32.
4. Jaillon P, Asmar R et al. Доклад на Европейском Обществе по артериальной гипертензии, Милан, 2001.
5. Emeriau J-P, Knauf H, Pujadas JO et al. A comparison of indapamide SR 1,5 mg with both amlodipine 5 mg and hydrochlorothiazide 25 mg in elderly hypertensive patients: a randomized double-blind controlled study. J Hypertens 2001; 19: 343–50.
6. Gosse P, Sheridan DJ, Zannad F et al. Regression of left ventricular hypertrophy in hypertensive patients treated with indapamide SR 1,5 mg versus enalapril 20 mg: the LIVE study. J Hypertens 2000; 18: 1465–75.
7. Marre M, Puig JG, Kokot F et al. Equivalence of indapamide SR and enalapril on microalbuminuria reduction in hypertensive patients with type2 diabetes: the NESTOR study. J Hypertens 2004; 22: 1613–22.
8. Beckett N, on behalf of HYVET Co-ordinating center, committees and investigators. Progress report of the hypertension in very elderly trial (HYVET). J Hypertens 2007; 25 (suppl. 2): S 233.
9. Ambrosioni E, Safar M, Degaute J-P et al. Low-dose antihypertensive therapy with 1,5 mg sustained-release indapamide: results of randomized double-blind controlled studies. European Study Group. J Hypertens 1998; 16: 1677–84.
10. Weidmann P. Metabolic profile of indapamide sustained-release in patients with hypertension. Drug Safety 2001; 24: 1155–65.
11. Leonetti G. Clinical positionning of indapamide sustained release 1,5 mg in management protocols for hypertension. Drugs 2000; 59 (suppl. 2): 27–38.
12. Петров В.И., Недогода С.В., Сабанов А.В. Ретроспективный клинико-экономический анализ результатов клинических исследований гипотензивных препаратов. Клин. исследования. 2004; 3–4: 36–43.
Авторы
М.В.Леонова
ГОУ ВПО РГМУ им. Н.И.Пирогова, Москва
ГОУ ВПО РГМУ им. Н.И.Пирогова, Москва
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.